Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.57 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.45 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | SENP5 | Q96HI0 | 1/20 | 0.43 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.43 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1895486 | 0.91 | HDAC1 (0.70) | HDAC1HDAC2HDAC3 | |
| SCHEMBL13036444 | 0.83 | HDAC1 (0.65) | HDAC1HDAC2HDAC3SENP5SENP2 | |
| SCHEMBL8250687 | 0.81 | HDAC1 (0.50) | HDAC1HDAC2HDAC3SENP5SENP2 | |
| SCHEMBL4552001 | 0.81 | BCL2L1 (0.55) | HDAC1BCL2L1TBXAS1 | |
| SCHEMBL3982575 | 0.80 | HDAC1 (0.83) | HDAC1BCL2L1HDAC2HDAC3SENP5 | |
| SCHEMBL17864888 | 0.77 | LMNA (0.61) | HDAC1PLAUHDAC2LMNASMN1; SMN2 | |
| SCHEMBL4255241 | 0.77 | HDAC1 (0.82) | HDAC1BCL2L1TBXAS1 | |
| Benzyl Benzylcarbamate SCHEMBL1136818 | 0.76 | PLAU (0.70) | HDAC1PLAUHDAC2TNKSTNKS2 | |
| SCHEMBL8866913 | 0.75 | HDAC1 (0.56) | HDAC1BCL2L1SMN1; SMN2 | |
| Benzyl Benzylcarbamate SCHEMBL9998166 | 0.74 | PLAU (0.68) | HDAC1PLAUHDAC2TNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834034-B2 | Benzothiophene derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090082308-A1 | Benzothiophene derivatives | MERCK SHARP & DOHME LLC | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082308-A1 | Benzothiophene derivatives | BRDT, HDAC5, BRPF3 | HDAC1 4/4885PLAU 4684/4885BCL2L1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.